儿童肾病综合征首次发作:延长激素减量 vs 标准泼尼松治疗
该III期随机双盲安慰剂对照试验纳入237例1-14岁初发激素敏感性肾病综合征患儿,比较16周延长泼尼松方案(总剂量3150 mg/m2)与8周标准方案(总剂量2240 mg/m2)。主要终点首次复发时间无显著差异(HR 0.87,95%CI 0.65-1.17,P=0.28),但延长方案显示短期健康经济学获益。
要点
- 延长初始泼尼松疗程至16周未改善首次复发时间或复发相关结局。
- 两组严重不良事件率无显著差异,标准疗程组行为问题更差但量表评分无差异。
- 延长疗程与质量调整生命年增加及成本节省相关,但置信区间宽。
核心结论
- 在英国激素敏感性肾病综合征患儿中,将初始泼尼松疗程从8周延长至16周未改善临床结局。
- 延长疗程显示短期健康经济学获益,包括资源使用减少和生活质量提高。
研究设计与样本
- 双盲、平行组、III期随机安慰剂对照试验,包含成本效果分析。
- 纳入237例1-14岁初发激素敏感性肾病综合征患儿,来自125个英国国家医疗服务体系地区综合医院和三级儿科肾脏病中心。
- 随机接受16周延长泼尼松疗程(总剂量3150 mg/m2)或8周标准疗程(总剂量2240 mg/m2),按意向性治疗分析。
主要发现
- 首次复发时间无显著差异(HR 0.87,95%CI 0.65-1.17,P=0.28)。
- 频繁复发肾病综合征发生率:延长组60/114(53%)vs 标准组55/109(50%),P=0.75。
- 激素依赖肾病综合征发生率:延长组48/114(42%)vs 标准组48/109(44%),P=0.77。
- 需要替代免疫抑制治疗:延长组62/114(54%)vs 标准组61/109(56%),P=0.81。
- 严重不良事件率:延长组19/114(17%)vs 标准组27/109(25%),P=0.13。
关键数值与推荐
- 延长疗程组试验药物完成后总泼尼松剂量为6674 mg,标准疗程组为5475 mg(P=0.07)。
- 延长疗程与平均增加0.0162质量调整生命年相关(95%CI -0.005至0.037)。
- 延长疗程与成本节省相关(差值-£1673,95%CI -£3455至£109)。
临床怎么用
- 对于初发激素敏感性肾病综合征患儿,延长初始泼尼松疗程至16周未显示临床获益。
- 临床决策时可考虑延长疗程的短期健康经济学获益,但需权衡证据不确定性。
局限性
- 成本节省的95%置信区间宽,包含无效值。
- 质量调整生命年增加的95%置信区间下限略低于0。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether extending initial prednisolone treatment from eight to 16 weeks in children with idiopathic steroid sensitive nephrotic syndrome improves the pattern of disease relapse. DESIGN: Double blind, parallel group, phase III randomised placebo controlled trial, including a cost effectiveness analysis. SETTING: 125 UK National Health Service district general hospitals and tertiary paediatric nephrology centres. PARTICIPANTS: 237 children aged 1-14 years with a first episode of steroid sensitive nephrotic syndrome. INTERVENTIONS: Children were randomised to receive an extended 16 week course of prednisolone (total dose 3150 mg/m2) or a standard eight week course of prednisolone (total dose 2240 mg/m2). The drug was supplied as 5 mg tablets alongside matching placebo so that participants in both groups received the same number of tablets at any time point in the study. A minimisation algorithm ensured balanced treatment allocation by ethnicity (South Asian, white, or other) and age (5 years or less, 6 years or more). MAIN OUTCOME MEASURES: The primary outcome measure was time to first relapse over a minimum follow-up of 24 months. Secondary outcome measures were relapse rate, incidence of frequently relapsing nephrotic syndrome and steroid dependent nephrotic syndrome, use of alternative immunosuppressive treatment, rates of adverse events, behavioural change using the Achenbach child behaviour checklist, quality adjusted life years, and cost effectiveness from a healthcare perspective. Analysis was by intention to treat. RESULTS: No significant difference was found in time to first relapse (hazard ratio 0.87, 95% confidence interval 0.65 to 1.17, log rank P=0.28) or in the incidence of frequently relapsing nephrotic syndrome (extended course 60/114 (53%) v standard course 55/109 (50%), P=0.75), steroid dependent nephrotic syndrome (48/114 (42%) v 48/109 (44%), P=0.77), or requirement for alternative immunosuppressive treatment (62/114 (54%) v 61/109 (56%), P=0.81). Total prednisolone dose after completion of the trial drug was 6674 mg for the extended course versus 5475 mg for the standard course (P=0.07). There were no statistically significant differences in serious adverse event rates (extended course 19/114 (17%) v standard course 27/109 (25%), P=0.13) or adverse event rates, with the exception of behaviour, which was poorer in the standard course group. Scores on the Achenbach child behaviour checklist did not, however, differ. Extended course treatment was associated with a mean increase in generic quality of life (0.0162 additional quality adjusted life years, 95% confidence interval -0.005 to 0.037) and cost savings (difference -£1673 ($2160; €1930), 95% confidence interval -£3455 to £109). CONCLUSIONS: Clinical outcomes did not improve when the initial course of prednisolone treatment was extended from eight to 16 weeks in UK children with steroid sensitive nephrotic syndrome. However, evidence was found of a short term health economic benefit through reduced resource use and increased quality of life. TRIAL REGISTRATION: ISRCTN16645249; EudraCT 2010-022489-29.
引用
- Webb NJA, Woolley RL, Lambe T, et al. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. BMJ. 2019. PMID: 31335316. doi:10.1136/bmj.l1800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。